President, CEO and Director · Jazz Pharmaceuticals plc (JAZZ)

Renee Gala

FY2025 is the first fiscal year CompBrief holds for Renee Gala as a named executive officer of Jazz Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$19,151,558

1st of 6 named executive officers at Jazz Pharmaceuticals by FY2025 total.

6 named officers on file for Jazz Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. Jazz Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed June 8, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-07.

Free

Get Renee Gala’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Renee Gala and every company like it: Velarion Intel, free for 3 days, no card →

Renee Gala compensation by year

Jazz Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Jazz Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$1,003,269
Bonus$0
Stock awards$16,138,433
Option awards$0
Non-equity incentive$1,980,000
Pension and deferred compensation$0
All other$29,856
Total$19,151,558

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 8, 2026, accession 0001232524-26-000029, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001232524-26-000029. Every figure is read from that document and cited to the page and table it appears in. Filed June 8, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU76,370$12,982,900—
PSU46,222$7,857,740—
PSU39,832$6,771,440—
RSU23,111$3,928,870—
RSU18,808$3,197,360—
RSU14,937$2,539,290—
RSU12,741$2,165,970—
RSU11,555$1,964,350—
RSU6,392$1,086,640—
RSU2,932$498,440—
RSU386$65,620—

Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

5 Form 4 lines since the FY2025 proxy (filed June 8, 2026)
current to 2026-11-07 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-03Sale10b5-11,000$225.37140,394
2026-10-06Sale10b5-12,000$236.40141,394
2026-09-08Sale10b5-12,000$243.03143,394
2026-09-08Tax withholding10b5-11,967$246.81145,394
2026-06-30Tax withholding—4,835$237.72147,361

The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Jazz Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Renee Gala · this pagePresident, CEO and Director$19,151,558
Bruce CozaddChairperson and Former CEO$18,834,836
Robert IannoneExecutive Vice President, Global Head of Research and Development and Chief Medical Officer$8,661,758
Philip JohnsonExecutive Vice President and CFO$7,544,473
Neena PatilExecutive Vice President and Chief Legal Officer$6,299,539
Samantha PearceExecutive Vice President, Chief Commercial Officer$6,076,127

Board service

Jazz Pharmaceuticals board · FY2025

How this board is paid

Company policy: Jazz Pharmaceuticals pays directors a $75,000 cash retainer and $400,000 in equity. As stated in Jazz Pharmaceuticals's FY2025 proxy.

The full Jazz Pharmaceuticals compensation record

free company brief

This page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Jazz Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Jazz Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order JAZZ

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Renee Gala's compensation dossier